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uregs (Fig. 1A–C). As reported in Fig. 1D, the number of CD25highC-
127lowFOXP3+ Tregs within the CD4+ population is equal in all
he groups of children. Our data conﬁrms that the number of
D4+CD25highCD127low ‘True’ Tregs remains unchanged in liver
isease with autoimmune traits, including AIH and NASH as
lready reported [1,6]. However, in children, the number of
D25highCD127lowFOXP3+ Tregs among CD4+ ranges from
etween 2.3% and 3.0%. In summary, all of these ﬁndings highlight
he importance of a ‘‘consensus’’ in the standardization of proto-
ols for evaluating the Tregs function in AIH and NASH.
In addition, we would raise a discussion concerning some
spects related to non-alcoholic steatohepatitis (NASH). Peiseler
t al. determined the intra-hepatic Tregs frequency by immuno-
istochemistry for FOXP3 in 8 NASH patients, in comparison to
IH [1], and found a higher percentage of FOXP3+ cells in AIH
atients when compared to NASH subjects, both in liver lobules
nd in portal tracts. Moreover, they determined that the FOXP3+
ells within the CD3+ population in the liver showed no statistical
ifferences between AIH and NASH patients. No information
bout the diagnosis and severity of NASH was provided by the
uthors. Further, the usage of the modiﬁed histological activity
ndex (mHAI) [7], for quantifying the degree of liver inﬂamma-
ion, is not suitable for NASH patients who are histologically eval-
ated by using the NAFLD Clinical Research Network criteria [8].
s liver-resident inﬂammatory cells are a key component in
AFLD, particularly in children [9], their role in the severity of
ASH-associated necroinﬂammation and ﬁbrosis requires partic-
lar attention. In fact, we demonstrated that CD3+ cells were sig-To the Editor:
We read with great interest a recent article published in this Jour-
nal by Peiseler et al. [1], together with the accompanying editorial
[2], regarding the T regulatory cells (Tregs) in autoimmune
hepatitis (AIH). Peiseler et al. found that CD4+CD25high
CD127lowFOXP3+ Tregs in AIH are ‘‘fully functional and not reduced
in frequency’’. Longhi et al. [3], who had previously published that
Tregs are functionally impaired in AIH, ﬁrst argued against the
methodology used for assessing the Tregs suppressor activity,
since Peiseler et al. employed an ‘‘utterly non-physiological’’ sup-
pressor/effector ratio. Peiseler et al. replied by stating that their
methodology for staining proliferating cells by carboxyﬂuores-
cein succinimidyl ester (CFSE) is more appropriate than
thymidine uptake and speciﬁcally stains the CD4+CD25 effector
T cells.
Another argument was raised regarding the choice of the Tregs
labeling gate that resulted in a lower Tregs frequency compared
with that reported by others [4]. The authors replied [5] by stating
that the frequency of peripheral blood Tregs in adults reported by
Garg et al. is ‘‘not vastly different from the frequencies reported by
us’’. Garg et al. [4] extrapolated that the Tregs number from
CD4+CD25high-labeled cells, considering only the top 1% of
CD25-staining CD4 T cells, as being estimated to be >98%
CD127low. We believe that the comparison of Tregs frequencies
is questionable and age-related, as demonstrated by our data.
Peripheral blood cells from 4 healthy, 4 AIH, and 4 non-alcoholic
steatohepatitis (NASH) children (age range: 10–14 years) were
used to evaluate frequencies of CD4+CD25highCD127lowFOXP3+vol. 57 j 1391–1402
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Fig. 1. Treg cells in liver diseases. (A–C) Identiﬁcation of Treg cells by ﬂow cytometry. (A) Dot plot showing the staining for CD4 and CD25 in T cells gated as CD3+CD4+.
Treg cells are CD4+CD25+ bright. (B) dot plot showing the coexpression of CD25 and FoxP3 in CD4+ T cells. Tregs are CD25+FoxP3+. (C) dot plot showing the coexpression of
CD25 and CD127 in CD4+ T cells. Treg cells are CD25+CD127+ low. Percentages of positive cells are indicated. A minimum of 50,000 live cell events were collected using
FACSCanto ﬂow cytometry (Becton & Dickinson, San Jose, CA, USA) and analyzed with DiVa software (Becton & Dickinson). (D) Statistical analysis of percentages of Treg
cells in controls, AIH and NASH patients. Histograms of mean and standard deviations of percentages of CD4+CD25high and CD25highCD127lowFox3P positive Treg cells in
peripheral blood lymphocytes of 4 healthy controls, 4 AIH, and 4 NASH patients. No statistical difference is observed within the analyzed groups (Mann–Whitney test,
p >0.05).
JOURNAL OF HEPATOLOGYniﬁcantly lower (p <0.01) in children with an NAFLD activity
score (NAS) P5 and ﬁbrosis with respect to children with NAS
<5. Furthermore, our preliminary data in 30 NAFLD children indi-
cates that liver-resident CD25+ cells are rare in this condition (not
shown). These ﬁndings oppose Peiseler et al. [1] when stating
about the presence of FOXP3+ in NASH.
Despite several criticisms, Peiseler’s study and Longhi’s com-
ments raise new questions and provide an experimental break-
through regarding the study of the Tregs frequency and its
function in inﬂammatory liver diseases. The role of the innate
and adaptive immunity in NAFLD/NASH still remains an open
and intriguing issue [10].
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autoimmune traits in liver diseases’’To the Editor:
We read with interest the comment of Fierabracci et al. on a
recent discussion between Longhi et al. [1] and us [2] on the fre-
quency of regulatory T cells (Treg) in autoimmune hepatitis
(AIH). This debate was in connection with our recent publication
demonstrating that, in contrast to previous reports, Treg frequen-cies in the blood of AIH patients are not decreased [3]. We gladly
acknowledge that Fierabracci et al. basically conﬁrm our ﬁnding
of unreduced Treg numbers in AIH.
However, the Treg frequencies in blood reported by us are
lower than those previously reported, which has been a matter
of debate between Longhi et al. [1] and us [2]. Fierabracci et al.2 vol. 57 j 1391–1402 1399
